Latest news with #RegencellBioscience
Yahoo
15 hours ago
- Business
- Yahoo
Silver's rise, Reddit's AI ad tools, Regencell Bioscience surges
Here are some of the stories Wall Street is watching on June 17. Stocks (^DJI, ^GSPC, ^IXIC) are trading lower on ongoing nervousness about the conflict between Israel and Iran. Silver (SI=F) is hitting levels not seen since February 2012. Reddit (RDDT) is continuing to see its stock rise after adding new AI ad tools. Regencell Bioscience (RGC)s shares are exploding higher after a 38-for-1 stock split. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.
Bloomberg
16 hours ago
- Business
- Bloomberg
Blistering Rally in Herbal Medicine Stock Mints $26 Billion Fortune
A blistering rally in a tiny, money-losing traditional Chinese medicine company's stock has vaulted its founder's net worth to among the world's 100 largest fortunes. The firm, Hong Kong-based Regencell Bioscience Holding Ltd., was for all intents and purposes trading as a microcap stock on the Nasdaq just eight weeks ago. But its shares have since exploded, gaining more than 46,000% this year as of Monday's close. The move has boosted the value of Chief Executive Officer Yat-Gai Au's 86% stake to $25.6 billion, according to the Bloomberg Billionaires Index, making Au's paper wealth greater than rich-list stalwarts such as Jerry Jones and Masayoshi Son.
Sydney Morning Herald
a day ago
- Business
- Sydney Morning Herald
The company with zero revenue that is worth $31 billion
A biotech stock focused on herbal medicine has surged by more than 64,000 per cent so far this year, although the company has made zero revenue, much less turned a profit. The unbelievable rally has transformed Regencell Bioscience Holdings, a penny stock as recently as April, to one worth more than $US20 billion ($30.7 billion) in market value. A year ago, the company had a market capitalisation of $US53 million. This is despite having a net loss of $US4.4 million for its fiscal year that ended June 2024, a 28 per cent decrease from the previous year. Regencell Bioscience this month said its board approved a 38-for-1 stock split. When the split took effect, shares rose as much as 434 per cent – their biggest one-day jump ever – to a record high, triggering more than 10 volatility halts. Shares of the company have been on a bizarre 640-fold tear in 2025, with little to no news released. The Hong Kong-based company, which debuted on the Nasdaq Capital Market in 2021, is in the research and development stage and has not generated any revenue since inception, according to its most-recent annual filing with the US Securities and Exchange Commission. A representative for Regencell didn't immediately respond to a Bloomberg request for comment. Incorporated in the Cayman Islands, the company aims to treat neurological conditions such as ADHD and autism spectrum disorder through traditional herb-based medicines, according to its website. Its traditional Chinese medicine (TCM) formula, which forms the basis of its product candidates, 'contains only natural ingredients without any synthetic components'. 'We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable,' the company said in an October filing.
The Age
a day ago
- Business
- The Age
The company with zero revenue that is worth $31 billion
A biotech stock focused on herbal medicine has surged by more than 64,000 per cent so far this year, although the company has made zero revenue, much less turned a profit. The unbelievable rally has transformed Regencell Bioscience Holdings, a penny stock as recently as April, to one worth more than $US20 billion ($30.7 billion) in market value. A year ago, the company had a market capitalisation of $US53 million. This is despite having a net loss of $US4.4 million for its fiscal year that ended June 2024, a 28 per cent decrease from the previous year. Regencell Bioscience this month said its board approved a 38-for-1 stock split. When the split took effect, shares rose as much as 434 per cent – their biggest one-day jump ever – to a record high, triggering more than 10 volatility halts. Shares of the company have been on a bizarre 640-fold tear in 2025, with little to no news released. The Hong Kong-based company, which debuted on the Nasdaq Capital Market in 2021, is in the research and development stage and has not generated any revenue since inception, according to its most-recent annual filing with the US Securities and Exchange Commission. A representative for Regencell didn't immediately respond to a Bloomberg request for comment. Incorporated in the Cayman Islands, the company aims to treat neurological conditions such as ADHD and autism spectrum disorder through traditional herb-based medicines, according to its website. Its traditional Chinese medicine (TCM) formula, which forms the basis of its product candidates, 'contains only natural ingredients without any synthetic components'. 'We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable,' the company said in an October filing.
Bloomberg
2 days ago
- Business
- Bloomberg
Herbal Medicine Stock With No Sales Rallies 64,000%
A biotech stock focused on herbal medicine has surged by more than 64,000% so far this year and yet, the company itself has made zero revenue — much less turned a profit. The unbelievable rally has transformed Regencell Bioscience Holdings Limited, a penny stock as recently as April, to one worth more than $20 billion in market value. A year ago, the stock had a market capitalization of just $53 million. This is despite the company having a net loss of $4.4 million for its fiscal year that ended June 2024, a 28% decrease from the previous year.
